Voyageur Pharmaceuticals CEO Brent Willis joins Proactive's Natalie Stoberman to share the latest results from its SmoothX comparative studies.

Willis says results of the double-blind testing showed that SmoothX was favoured on drinkability and taste by 75% of patients compared to the competing product.

Before SmoothX goes to market, Willis adds a medical white paper is currently in preparation that will provide an in-depth analysis of the studies and insights into the effectiveness of SmoothX to educate and inform doctors and medical staff about the product's benefits for abdominal CT diagnostic imaging procedures.

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com